Log In
BCIQ
Print this Print this
 

CRB0017

  Manage Alerts
Collapse Summary General Information
Company Rottapharm Biotech s.r.l.
Description mAb against ADAM metallopeptidase with thrombospondin type 1 motif 5 (ADAMTS5)
Molecular Target ADAM metallopeptidase with thrombospondin type 1 motif 5 (ADAMTS5)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationOsteoarthritis
Indication DetailsTreat osteoarthritis (OA)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/11/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today